Kate Street

Interest in the gut microbiome continues to grow as research reveals its influence extends far beyond gastrointestinal health.1 Home to trillions of microorganisms, the gut microbiome plays a central role in nutrient metabolism, intestinal barrier integrity, immune regulation, and communication with distant organs through the gut-organ axes.1 When this microbial ecosystem is disrupted, a state known as dysbiosis occurs and has been associated with a range of adverse health outcomes, including altered immune function, impaired mood, cardiometabolic disease, and chronic inflammation.1As understanding of the microbiome expands, so too has interest in probiotic supplementation. While traditional probiotics such as Lactobacillus and Bifidobacterium remain widely used, a different category of probiotic with a unique adaptive trait has attracted increasing scientific attention: spore-forming probiotics.2 <h3>What are spore-forming probiotics?</h3>Spore-forming probiotics are live microorganisms, primarily from the Bacillus genus, that have the ability to produce endospores, highly resilient structures that protect the organism during periods of environmental stress.3 Unlike many conventional probiotic strains, these spores can withstand adverse conditions including heat, dryness, oxygen exposure, and stomach acidity, contributing to their unique biological characteristics.3<h3> </h3><h3>What makes spore-forming probiotics different?</h3>One of the challenges facing many conventional probiotics is maintaining viability throughout manufacturing, storage, and gastrointestinal transit.4 Exposure to moisture, temperature fluctuations, and gastric acidity can reduce the number of live organisms that ultimately reach the intestine.4The protective spore coat enables spore-forming probiotics to remain dormant until they reach favourable conditions within the gut, enhancing stability during storage and survival through gastric transit.5 This resilience allows spores to withstand the challenging conditions of the gastrointestinal tract, including acidic pH, bile salts, and competition from resident microbes.5 As a result, many spore-forming probiotic formulations are shelf-stable and do not require refrigeration.5,6 Improved survival may increase delivery of viable organisms to the intestine, where they can exert their biological effects (see Figure 1).5 It is worth being clear, however, that surviving gastric transit is a delivery advantage rather than a clinical outcome in its own right. Efficacy still has to be demonstrated strain by strain in controlled trials, and appropriately formulated non-spore-forming strains can also reach the intestine in adequate numbers.2,4<img src="https://images.contentstack.io/v3/assets/blt948bd74310fc0ad0/bltd19b191800790396/6ab4b8a569958cb7d4dc8cac/spore-forming-figure1.png" alt="spore-forming-figure1.png" class="embedded-asset" />Figure 1. Mechanism of action of spore-forming probiotics.5
<h3></h3><h3>Activity within the gastrointestinal tract</h3>Once in the small intestine, spores encounter germination signals derived from bile acids and dietary nutrients, indicating a favourable environment for growth and triggering their transition into metabolically active bacterial cells.7 As those germination cues are meal-associated, dosing with or immediately after food is the more physiologically logical instruction, although timing has not yet been tested as a variable in clinical trials.7These cells can then go on to produce digestive enzymes, interact with the resident gut microbiota, and influence the local intestinal environment.8 Research suggests these interactions may support microbial balance, intestinal barrier integrity, and immune signalling pathways.8It is worth being precise about what happens next. Bacillus species used as probiotics are transient rather than resident members of the microbiota. Adhesion to the intestinal epithelium is weak, and organisms are generally cleared in the faeces within roughly four to seven days of the last dose, which is precisely why continued daily intake is required to sustain an effect.12 This is a useful thing to say out loud to patients, who often assume a probiotic will permanently repopulate the gut.<h3> </h3><h3>Spotlight on Bacillus coagulans</h3>While several Bacillus species are used in probiotic formulations, Bacillus coagulans is among the most extensively studied for its potential role in digestive and immune health.9 Unlike other Bacillus species used as probiotics, B. coagulans combines the resilience of a spore-forming organism with the ability to produce lactic acid once metabolically active in the gut, helping to support a favourable intestinal environment.9Clinical studies have reported improvements in symptoms associated with irritable bowel syndrome (IBS).9,10 Benefits are thought to result from a combination of microbiome modulation and interactions with immune and inflammatory pathways.9<h3></h3><hr /><h3>Research highlight</h3>A 2024 systematic review and meta-analysis of seven randomised controlled trials reported that B. coagulans improved several IBS symptom domains, including abdominal pain, bloating, urgency, straining, and overall symptom severity, with no serious adverse events across the included trials.10The authors were explicit about the limitations: the included trials were small, statistical heterogeneity was substantial, and the analysis pooled several different commercial strains rather than assessing them individually, with pooled findings for bloating inconsistent between strains.10<hr /><h3>Clinical considerations from <a href="https://drbradleech.com/">Dr Brad Leech</a></h3>For practitioners weighing up whether a spore-forming probiotic belongs in a given case, a few points are worth holding in mind.<ul><li>Check the full strain designation. Check the label for a full strain designation, not just a species name. If the strain is not identified, the published evidence cannot be attributed to that product.</li><li>Use a defined dose, duration, and review point. Most positive trials used approximately 1 to 2 billion CFU daily for between four weeks and three months. Set a review point at around eight weeks, define in advance what a meaningful response looks like, and be willing to stop rather than continue indefinitely.</li><li>Consider dose timing. Dose with or immediately after food, since germination depends on bile acid and nutrient signals.</li><li>Explain the need for ongoing intake. Benefit depends on ongoing intake because these organisms are cleared within days of stopping. Raise this at the outset so the patient is not surprised, and decide together whether the goal is ongoing symptom control or a time-limited trial.</li><li>Complete the appropriate diagnostic work. A spore-forming probiotic does not replace the diagnostic work. Exclude coeliac disease, inflammatory bowel disease, and other red flags before treating symptoms that resemble IBS, and keep dietary, sleep, and stress-related contributors in view. Evidence is also thinner for constipation-predominant IBS than for diarrhoea-predominant IBS.</li><li>Prioritise strain-level evidence. The decision in front of you is rarely a spore former versus nothing. It is a spore former versus a conventional strain that has its own trial evidence. Choose on the strength of the strain-level evidence for the outcome you are targeting, not on the delivery mechanism.</li><li>Consider practical advantages separately from efficacy. The shelf-stability of these formulations is genuinely useful where refrigeration, travel, or adherence is the limiting factor. This is a legitimate basis for product selection in its own right, quite separate from any claim of superior efficacy.</li><li>Be measured when discussing use alongside antibiotics. The rationale is reasonable, since a dormant endospore is not a target for antibacterials in the way a vegetative cell is, but robust strain-specific human data in that setting remain limited.
</li></ul><hr /><h3>Statement from <a href="https://drbradleech.com/">Dr Brad Leech</a></h3>"The reason spore-forming probiotics have held my attention is not their durability. It is what that durability makes possible. A dormant endospore that reaches the small intestine intact and then germinates in response to bile acids and nutrient signals is a genuinely different delivery proposition to a vegetative cell that has to survive the stomach as it is.But survival is the beginning of the clinical question, not the answer to it. What matters at the point of prescribing is whether a specific, named strain has been shown to shift outcomes that patients actually notice, at a dose and over a duration you can replicate in practice.For Bacillus coagulans, a small number of well-characterised strains have done exactly that in IBS. My advice to practitioners is unglamorous but useful. Read the label for the full strain designation, match it to the trial, set a review point at eight weeks, and remember that these organisms are transient. The benefit lasts as long as the intake does."<hr /><h3>Safety</h3>Spore-forming probiotics are generally well tolerated in healthy individuals. However, caution is advised in people who are severely immunocompromised, as their underlying condition may increase susceptibility to adverse events associated with live microorganisms.5,11 In these cases, probiotic supplementation should be undertaken under the guidance of an appropriately qualified healthcare professional.<h3> Conclusion</h3>As probiotic research continues to evolve, spore-forming strains are emerging as a distinct category of probiotics with unique clinical characteristics. Their ability to survive environmental and gastrointestinal challenges enhances delivery of viable organisms to the intestine, while emerging evidence suggests benefits for digestive health, microbiome modulation, and immune health. Among these, B. coagulans has shown promise, highlighting the growing role of spore-forming probiotics in evidence-informed microbiome care.<h3> References</h3>1 Alali MA, Shori AB. Understanding the human gut microbiome: from composition to disease association. Front Microbiomes. 2026;5:1717288. doi:10.3389/frmbi.2026.17172882 Ramírez A, Bermúdez-Luque A, Román-Camacho JJ, Martín-García FJ, Moreno-García J, Güngörmüşler M, et al. Exploring the future of probiotics with innovations in delivery systems and market insights. Food Biosci. 2025;71:107029. doi:10.1016/j.fbio.2025.1070293 Crivelli XB, Cundon C, Bonino MP, Sanin MS, Bentancor A. The complex and changing genus Bacillus: a diverse bacterial powerhouse for many applications. Bacteria. 2024;3(3):256–70. doi:10.3390/bacteria30300174 Sengun I, Kirmizigul Peker A, Sharma H, Rathod NB, Kudre TG, Szymkowiak A, et al. Factors affecting the viability of probiotics in various food products: a review of current knowledge. Front Microbiol. 2026;17:1893153. doi:10.3389/fmicb.2026.18931535 Mazzantini D, Ghelardi E. Spore-forming probiotics and their mechanisms of action: a particular focus on Alkalihalobacillus clausii. Nutrients. 2026;18(9):1378. doi:10.3390/nu180913786 Soares MB, Almada CN, Pereira EPR, Ferreira BM, Balthazar CF, Khorshidian N, et al. Spore-forming probiotic bacteria: characteristics, health benefits, and technological aspects for their applications in foods and beverages. Trends Food Sci Technol. 2023;138:453–69. doi:10.1016/j.tifs.2023.06.0297 Koopman N, Remijas L, Seppen J, Setlow P, Brul S. Mechanisms and applications of bacterial sporulation and germination in the intestine. Int J Mol Sci. 2022;23(6):3405. doi:10.3390/ijms230634058 Zhu J, Chen Y, Imre K, Arslan-Acaroz D, Istanbullugil FR, Fang Y, et al. Mechanisms of probiotic Bacillus against enteric bacterial infections. One Health Adv. 2023;1(1). doi:10.1186/s44280-023-00020-09 Cao J, Yu Z, Liu W, Zhao J, Zhang H, Zhai Q, et al. Probiotic characteristics of Bacillus coagulans and associated implications for human health and diseases. J Funct Foods. 2020;64:103643. doi:10.1016/j.jff.2019.10364310 AbdelQadir YH, Nabhan AI, Althawadi YJ, Belal MM, Feiter YY, Madian MS, et al. Bacillus coagulans as a potent intervention for treating irritable bowel syndrome: a systematic review and meta-analysis of randomized control trials. Gastroenterol Endosc. 2024;2(1):7–18. doi:10.1016/j.gande.2023.11.00111 Oprișanu M, Grigore-Gurgu L, Bahrim GE. Postbiotics functionality and safety evaluation of LAB and spore-forming probiotics. J Funct Foods. 2026;143:107411. doi:10.1016/j.jff.2026.10741112 Liang J, Li C, Chen Z, Guo F, Dou J, Wang T, et al. Progress of research and application of Heyndrickxia coagulans (Bacillus coagulans) as probiotic bacteria. Front Cell Infect Microbiol. 2024;14:1415790. doi:10.3389/fcimb.2024.1415790

<h3>Key highlights
</h3><ul><li>Spore-forming probiotics use a protective endospore structure to survive environmental and gastrointestinal stressors.</li><li>Their enhanced stability allows many formulations to remain shelf-stable without refrigeration.</li><li>Once germinated in the small intestine, Bacillus species can interact with the gut microbiota and support digestive function.</li><li>Specific Bacillus coagulans strains, rather than the species as a whole, have demonstrated benefits for digestive discomfort, bloating, abdominal pain, and other IBS-related symptoms in randomised controlled trials.</li><li>Spore-forming probiotics are transient residents of the gut rather than permanent colonisers, so any benefit depends on continued daily intake.</li></ul>

Key highlights

Recommended for you

Fenugreek | Supporting women through menopause

Milk Thistle | From liver support to metabolic balance

Why research is turning to Bacopa monnieri for brain ageing

Optimising exercise performance